“Hedge funds are certainly looking to capitalize on the enthusiasm for private equity,” says an EY partner.
Two Sigma, one of the world’s largest quantitative hedge fund managers, has raised $1.2 billion for its new private equity unit, Sightway Capital.
Sightway reached the final close of its first fund, Sightway Capital I, the firm said Tuesday. Commitments came from a “diverse group of institutional investors,” including Massachusetts’ public pension fund, which approved investing as much as $500 million with Sightway last year.
“With the closing of our first fund and the support of our new partners, we believe Sightway Capital is well positioned to build on the current momentum of our portfolio companies,” division CIO Wray Thorn said in a statement. “We plan to invest this additional capital to further scale our established platform company investments and to drive long-term value for our investors.”
Two Sigma first began exploring opportunities in private capital back in 2008, according to the Sightway website. The quant firm launched Sightway in January of last year as a way of “building on these established investment capabilities and continuing its differentiated investment approach.”
Two Sigma’s push into private equity reflects a larger trend of hedge fund firms diversifying with the hot asset class and other non-traditional strategies, according to EY. The consulting firm’s 2019 global alternative fund survey, published last week, found that 26 percent of hedge funds offered a private equity product.
“There is high investor appetite for these products,” said Ryan Munson, a partner in EY’s asset and wealth management practice. “Hedge funds are certainly looking to capitalize on the enthusiasm for private equity.”
While hedge funds in general have experienced a decline in popularity in recent years, private equity funds have been magnets for institutional capital. According to EY, private equity accounts for about a quarter of allocators’ alternatives portfolios, up from 18 percent in 2018. Hedge funds, by comparison, declined from 40 percent to 33 percent over the same period.
“In today’s environment, there’s a view that if you’re able to have a diversified portfolio of products to go to market with, that will help you attract a diversified base of investors and help with the overall performance of your firm,” Munson said. “I certainly think we’re going to continue to see this trend of managers not looking to be one-trick ponies but having variety of products.”
Source: Institutional Investor
Read other recent News
Valuation differences halt EQT’s Oxford Biomedica takeover push
Valuation differences halt EQT’s Oxford Biomedica takeover push EQT has opted not to proceed with a takeover offer for Oxford Biomedica after the British cell and gene therapy manufacturer rejected four separate proposals, Reuters reported. Oxford Biomedica confirmed...
Novacap closes $3.8bn Tech Fund VII, surpassing target by over $1bn
Novacap closes $3.8bn Tech Fund VII, surpassing target by over $1bn Novacap has closed its Technologies Fund VII at nearly $3.8bn, exceeding its $2.75bn target by more than $1bn in under a year, the firm announced. The vehicle marks Novacap’s largest fund to date and...
L Catterton partner Todd Bartee takes helm at Tonal as private equity reshapes connected fitness
L Catterton partner Todd Bartee takes helm at Tonal as private equity reshapes connected fitness L Catterton has strengthened its operational oversight at portfolio company Tonal by appointing Operating Partner Todd Bartee as Chief Executive Officer. Bartee succeeds...